Highly active multiple sclerosis: An update

Díaz, Cindy; Zarco, Luis Alfonso; Rivera, Diego Miguel

doi:10.1016/j.msard.2019.01.039

Cited by 82 publications

(65 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a subgroup of RRMS patients who have a more aggressive disease course called highly active MS that has been estimated to comprise about 4%‐15% of the patients . There is no consensus criteria or treatment algorithms for these patients, but MRI lesions that enhance gadolinium despite treatment, an EDSS scale of 4 points at 5 years of onset of the disease, no response to treatment with one or more DMTs for at least one year and multiple relapses (two or more) with incomplete recovery in the ongoing year, belong to the criteria.…”

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis in Finland 2018—Data from the national register

et al. 2019

View full text Add to dashboard Cite

Objectives:Finland is a high-risk multiple sclerosis (MS) region, but a national MS register has not existed until 2014. In this paper, we present the Finnish MS register variables and data collected by 31 December 2018. Materials and Methods:Numbers and data counts of MS patients in the register (ICD-10 code G35) are presented. The disease types and proportion of patients receiving disease-modifying treatments (DMTs) were analysed in five hospital districts with most complete data sets. MS prevalence in Finland was estimated using administrative hospital discharge data as an additional resource.Results: There were a total of 8722 MS patients in the Finnish MS register by 31December 2018 (71.5% females). Mean age at MS diagnosis was 38.7 years and peak prevalence was at age 50-54 years. Disease course was relapsing remitting (RRMS) in 66.7%, secondary progressive (SPMS) in 13.5%, and primary progressive (PPMS) in 7.9% of the 5365 MS patients in the selected districts with most complete data. A total of 66.0% of RRMS patients, 19.6% of SPMS patients and 9.9% of PPMS patients were receiving DMTs. By combining MS register data with databases of those hospitals that had not joined the register, the nationwide prevalence estimate was between 10 and 11 thousand patients (corresponding to crude prevalence 180-200/100 000). Conclusions:The Finnish MS register is currently used in 15/21 Finnish hospital districts. By register integration into the electronic patient files, the coverage of the register has increased to approximately 80% of the estimated Finnish MS population.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis in Finland 2018—Data from the national register

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Approximately 4-14% of all MS patients, depending on the definition used, already have a highly active disease course from the onset [3]. During the disease trajectory, this subgroup of patients is marked by a rapid accumulation of functional deficits and MRI activity, despite treatment with one or more disease-modifying drugs (DMDs) [4].…”

Section: Introductionmentioning

confidence: 99%

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

et al. 2019

View full text Add to dashboard Cite

Introduction:Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted. Methods: The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the CAM. Modelled patients were 280 adults with highly active relapsing multiple sclerosis eligible for disease-modifying treatment. Intervention was cladribine tablets, a new and reimbursed oral treatment for highly active

show abstract

“…Approximately 350,000 individuals in the United States and 2.5 million individuals worldwide have multiple sclerosis. Almost 10% of the cases present before the age of 18 [237,238]. The global MS drug market was valued at US$16.3 billion in 2016, expecting to reach US$27.8 billion by 2025 [239].…”

Section: Neurological Disordersmentioning

confidence: 99%

Clinical Pharmacists in Chronic Care

Mohiuddin¹

2019

GJMR

View full text Add to dashboard Cite

Pharmacy practice has changed significantly lately. The professionals have the chance to contribute straightforwardly to patient consideration so as to lessen morbimortality identified with medication use, promoting wellbeing and preventing diseases. Healthcare organizations worldwide are under substantial pressure from increasing patient demand. Unfortunately, a cure is not always possible particularly in this era of chronic complications, and the role of physicians has become limited to controlling and palliating symptoms.The increasing population of patients with longterm conditions are associated with high levels of morbidity, healthcare costs and GP workloads. Clinical pharmacy took over an aspect of medical care that had been partially abandoned by physicians. Overburdened by patient loads and the explosion of new drugs, physicians turned to pharmacists more and more for drug information, especially within institutional settings. Once relegated to counting and pouring, pharmacists headed institutional reviews of drug utilization and served as consultants to all types of health-care facilities. In addition, when clinical pharmacists are active members of the care team, they enhance proficiency by: Providing critical input on medicine use and dosing. Working with patients to solve problems with their medications and improve compliance.

show abstract

Highly active multiple sclerosis: An update

Cited by 82 publications

References 75 publications

Multiple sclerosis in Finland 2018—Data from the national register

Multiple sclerosis in Finland 2018—Data from the national register

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Clinical Pharmacists in Chronic Care

Contact Info

Product

Resources

About